Skip to main navigation
logo
  • Overview
  • Corporate
    • Corporate Profile
    • Management
    • Board of Directors
    • Key Advisors
    • Corporate Governance
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Quarterly Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • IR Contacts

News & Events

News Releases

News Releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
2021.08.19
Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab)
2021.08.12
Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board
2021.07.22
Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
2021.07.07
Adagene Announces Authorization of Share Repurchase Program up to US$20 Million
2021.06.16
Adagene Announces Inclusion in FTSE Russell Indexes

Pagination

  • First page « first
  • Previous page ‹ previous
  • …
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Current page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Next page next ›
  • Last page last »
Displaying 41 - 45 of 64

Shareholder Tools

  • © 2023 Adagene Inc.

Footer Bottom

  • Home
  • Privacy
  • Terms of Use
  • Contact
  • Site Credits
  • LinkedIn